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OBJECTIVE — Weperformedarandomizedtrialtocomparethreeinsulin-titrationprotocols
for tight glycemic control (TGC) in a surgical intensive care unit: an absolute glucose (Matias)
protocol, a relative glucose change (Bath) protocol, and an enhanced model predictive control
(eMPC) algorithm.
RESEARCH DESIGN AND METHODS — A total of 120 consecutive patients after
cardiac surgery were randomly assigned to the three protocols with a target glycemia range from
4.4 to 6.1 mmol/l. Intravenous insulin was administered continuously or in combination with
insulinboluses(Matiasprotocol).Bloodglucosewasmeasuredin1-to4-hintervalsasrequested
by the protocols.
RESULTS — The eMPC algorithm gave the best performance as assessed by time to target
(8.8  2.2 vs. 10.9  1.0 vs. 12.3  1.9 h; eMPC vs. Matias vs. Bath, respectively; P  0.05),
averagebloodglucoseafterreachingthetarget(5.20.1vs.6.20.1vs.5.80.1mmol/l;P
0.01), time in target (62.8  4.4 vs. 48.4  3.28 vs. 55.5  3.2%; P  0.05), time in hyper-
glycemia 8.3 mmol/l (1.3  1.2 vs. 12.8  2.2 vs. 6.5  2.0%; P  0.05), and sampling
interval(2.30.1vs.2.10.1vs.1.80.1h;P0.05).However,timeinhypoglycemiarisk
range(2.9–4.3mmol/l)intheeMPCgroupwasthelongest(22.21.9vs.10.91.5vs.13.1
1.6; P  0.05). No severe hypoglycemic episode (2.3 mmol/l) occurred in the eMPC group
compared with one in the Matias group and two in the Bath group.
CONCLUSIONS — TheeMPCalgorithmprovidedthebestTGCwithoutincreasingtherisk
of severe hypoglycemia while requiring the fewest glucose measurements. Overall, all protocols
were safe and effective in the maintenance of TGC in cardiac surgery patients.
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T
he landmarkLeuvenStudy(1)demon-
stratedthatintensiveinsulintherapytar-
geted to maintain normoglycemia
between 4.4 and 6.1 mmol/l reduced mor-
tality in the surgical intensive care unit
(ICU) and markedly decreased the fre-
quency of organ complications associated
with critical illness. Other studies con-
ﬁrmed these ﬁndings, particularly in car-
diac surgery patients (2–5), whereas others
still questioned the safety and universality
ofthebeneﬁcialeffectoftightglycemiccon-
trol (TGC) in different subgroups of criti-
cally ill patients (6–9).
In principle, the need to maintain eu-
glycemia in the ICU has been widely ac-
cepted. Numerous insulin protocols of
variable effectiveness have been devel-
oped (5,10–12). Most of these protocols
require considerable ICU staff training
and experience, and some call for intu-
itive decisions. In consequence, some
protocols may lead to inconsistent ap-
plication, mistakes, or misinterpretation.
Furthermore, frequent glucose measure-
ments, essential for TGC, may markedly
increasetheworkloadofICUnursingstaff
(13,14).
Most newly developed glucose man-
agement protocols are compared against
the so-called standard protocols with
which adequate glucose control is not
usually achieved. Head-to-head compari-
son of speciﬁcally designed TGC proto-
cols (15–18) is not available, although
such information is of the highest impor-
tance from the practical point of view.
We carried out such a direct compar-
ison of three different, effective, and pub-
lished TGC management protocols with a
major focus on TGC effectiveness and
safety. We performed a monocenter ran-
domized trial and compared a protocol
based on the absolute glucose value, the
Matias protocol (15,17); a protocol based
on the relative glucose change, the Bath
protocol (19); and a computer-based
model predictive control algorithm with
variablesamplingrate(eMPC)(16)devel-
oped within the 6th Framework Pro-
gramme e-Health Project “Closed Loop
InsulinInfusionforCriticallyIllPatients.”
RESEARCH DESIGN AND
METHODS— Patients, aged 18–90
years, admitted to the postoperative ICU
after elective cardiac surgery, were in-
cluded. Written informed consent was
obtained from all participants before be-
ing enrolled in the study. The study was
approved by the Human Ethical Review
Committee, 1st Faculty of Medicine and
General University Hospital, Prague,
Czech Republic, and was performed in
accordance with the guidelines proposed
in the Declaration of Helsinki. Exclusion
criteria were insulin allergy, mental inca-
pacity, and language barrier.
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tients; 40 patients were randomly as-
signed into the Matias, Bath, and eMPC
protocol treatment groups regardless of
their preoperative or admission glycemia
levels. The TGC protocols were started
after patients’ admission to the ICU after
arrival from the operating theater and
lasted until the end of the ICU stay. Be-
causethedurationoftheICUstayandthe
total monitoring time differed among pa-
tients, only data for up to 48 h were used
for the comparison of the protocols. For-
ty-eight hours of ICU stay were accom-
plishedin109of120patientsincludedin
the study. The mean follow-up time was
46.7  0.5 h for the Matias, 45.7  0.7 h
for the Bath, and 47.2  0.3 h for the
eMPC protocols, respectively.
Target glucose range
The target glucose range was 4.4–6.1
mmol/l, which has been demonstrated to
reduce mortality and morbidity (1). No
routine protocol was used for periopera-
tive glycemia control.
Blood glucose monitoring, insulin
treatment regimens, and nutrition
Bloodglucosewasmonitored,andinsulin
was administered according to the rules/
suggestions of each protocol. Undiluted
arterial blood for measurement of blood
glucose was drawn from an arterial line,
inserted for routine monitoring proce-
dures.Wholebloodglucosewasanalyzed
by a standard point-of-care testing device
(ABL 700; Radiometer Medical, Copen-
hagen, Denmark).
Insulin (Actrapid HM; Novo Nordisk,
Baegsvard,Denmark)wasgiveninacentral
venous line as a continuous infusion (Bath
andeMPCprotocols)orasacombinationof
a continuous infusion and boluses (Matias
protocol). A standard concentration of 50
IU of insulin in 50 ml 0.9% NaCl was used.
In all patients, infusion of a 10% glucose
solution was initiated upon admission to
ICU with a glucose dose of 2.5 g/kg ideal
body weight (height in centimeters minus
100) per hour and lasted for 18 h, when
normal oral food intake was started. In pa-
tients receiving mechanical ventilation, the
glucose infusion lasted for 48 h, and then
standard enteral nutrition was initiated.
Clinicalparametersandpatients’clin-
ical history data including age, sex, race,
height, weight, BMI, EuroSCORE (the
European System for Cardiac Operative
Risk Evaluation that identiﬁes a number
ofriskfactors,whichhelptopredictmor-
tality from cardiac surgery), history of di-
abetes, and type of surgery were collected
prospectively. Adverse events, medica-
tion, and nutrition were continuously
monitored and documented.
Outcome measures
Parametersfortheassessmentoftheeffec-
tiveness of different TGC management
protocolswereasfollows:entirestudyav-
erage glycemia level; time to the target
range of 4.4–6.1 mmol/l (80–110 mg/
dl); average glucose level after the target
rangewasreached;numberofhypoglyce-
mic episodes (blood glucose 2.9 mmol/
l); time within the target range; time
between 2.9 and 4.3 mmol/l (54–70 mg/
dl) with no clinical manifestations of hy-
poglycemia but indicating risk for
hypoglycemia; time between 6.2 and 8.3
mmol/l (110–150 mg/dl) indicating risk
of hyperglycemia; time in 8.3 mmol/l
(150 mg/dl) indicating hyperglycemia;
and sampling interval indicating work-
load. The percentage of time in the target
range was calculated as number of values
inthetargetrangeineachpatient/number
of measurements  100.
The three TGC management protocols
were implemented by the ICU nursing staff
with supervision by ICU doctors as re-
quired. Protocol training was performed by
the ICU physician and a departmental
nurse, usually individually, at bedside. A
3-month period was devoted to the imple-
mentation of the Bath insulin protocol,
whereas the Matias and eMPC protocols
have been used in the ICU previously.
Statistical analysis
Statistical analysis was performed using
STATISTICA software (StatSoft, Tulsa,
OK). The protocols were compared using
ANOVA followed by a Holm-Sidak test,
Student’s t test, or Mann-Whitney U test
as appropriate. The signiﬁcance level was
set at P  0.05.
Description of TGC glucose
management protocols
The TGC glucose management protocols
are described in online appendices 1–3,
available at http://care.diabetesjournals.
org/cgi/content/full/dc08-1851/DC1.
RESULTS— The baseline characteris-
tics of the study patients at the time of
admissiontotheICUarelistedinTable1.
The study groups did not differ with re-
spect to age, BMI, EuroSCORE, type of
surgery,baselinebloodglucoselevel,oroc-
currence of diabetes. Blood glucose control
characteristics are shown in Table 2 and
Figs. 1 and 2, respectively.
Table 2 demonstrates signiﬁcantly
betterbloodglucosecontrolwasachieved
in the eMPC group compared with the
Matias and the Bath groups: entire study
average glucose (5.9  0.2 vs. 6.7  0.1
vs. 6.5  0.2 mmol/l; P  0.05) and per-
centage of time within the target range
(46.6  3.0 vs. 38.2  2.9 vs. 39.7 
3.1%, P  0.05). To better describe and
compare TGC associated with each pro-
tocol, we divided glucose proﬁles into the
period before reaching the target range
(Table 2 and Fig. 1) and the period after
reaching the target range (Table 2). With
respect to the time to target range, the
eMPC protocol performed signiﬁcantly
better than the Matias and Bath protocols
(Table2;Fig.2).Intheperiodafterreach-
ing the target range, the eMPC algorithm
showed superior performance relative to
the Matias and Bath protocols with re-
spect to average glycemia (5.2  0.1 vs.
6.2  0.1 vs. 5.8  0.1 mmol/l; P 
0.05),timeintargetrange(62.84.4vs.
48.4  3.2 vs. 55.5  3.2% of time; re-
spectively, P  0.05), time in risk of hy-
perglycemia (13.7  2.6 vs. 27.5  2.2
vs. 24.5  2.4% of time; P  0.05), and
Table 1—Baseline characteristics of patients after cardiac surgery at the time of admission to
the ICU
Matias Bath eMPC
Age (years) 69.0  1.7 67.8  1.4 68.2  1.1
Female sex 14 15 12
Caucasian ethnicity (%) 100 100 100
BMI (kg/m
2) 28.4  0.35 27.3  1.0 27.8  0.8
EuroSCORE (logistic) 4.2  0.8 3.9  0.7 4.4  0.9
Type of surgery
CABG 28 24 12
Valve replacement 4 16 24
CABG  valve replacement 8 – 4
History of diabetes 14 12 16
Data are means  SEM or n. n  40 patients/protocol. CABG, coronary artery bypass graft.
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12.8  2.2 vs. 6.5  2.0% of time; P 
0.05) (Table 2).
The average insulin infusion rate and
the total insulin dose throughout the en-
tire study were signiﬁcantly higher in the
eMPCcomparedwiththeMatiasandBath
protocols(meaninsulinrate5.11.0vs.
3.7  0.4 vs. 4.1  0.5 IU/h; P  0.05).
The average sampling interval, as an indi-
cator of workload, was signiﬁcantly
shorter in the Bath versus both the Matias
and eMPC groups (Table 2). Two epi-
sodes of severe hypoglycemia deﬁned as
glycemia 2.3 mmol/l were observed
during the study in the Bath group and
one episode in the Matias group, whereas
no such episode occurred in the eMPC
group. All three hypoglycemic episodes
were classiﬁed as “asymptomatic” and
were not related to established major risk
factors of ICU hypoglycemia such as nu-
tritional interruption, delayed glucose
measurement, or drug administration.
CONCLUSIONS— In the present
study we compared the performance and
safety of three insulin-titration protocols
for TGC in the postoperative period in
cardiac surgery patients. We showed that
the most satisfactory glucose control was
achieved with a computer-based eMPC
algorithm, whereas the use of the relative
glucose value–based Bath protocol re-
sulted in less satisfactory glucose control.
The absolute glucose value–based algo-
rithm, the Matias protocol, showed the
least satisfactory performance. Impor-
tantly, all three protocols were reasonably
safe. Only three severe hypoglycemic epi-
sodes (blood glucose 2.3 mmol/l) oc-
curred throughout the entire study.
Strikingly,nosuchepisodewasnotedinthe
eMPC group that achieved the best glucose
control among the three protocols.
The results of our study further un-
derscore the fact that the ability to cor-
rectly implement a glucose management
protocol is the key prerequisite to suc-
cessful and safe glucose control in criti-
cally ill patients. Our ICU has 6 years
experiencewiththeuseoftheMatiaspro-
tocol and 4 years’ experience with testing
the eMPC algorithm, whereas the Bath
protocol has not been used in our center
before. However, after a 3-month imple-
mentation period, our ICU staff was able
to successfully use all three protocols
without any major problems or safety
concerns. This experience differs mark-
edly from the two large multicenter stud-
ies with TGC, the Glucontrol Study and
the Volume Substitution and Insulin
Therapy in Severe Sepsis (VISEP) Study,
that were discontinued because of exces-
sive risk of hypoglycemia. It is possible
that insufﬁcient time for insulin protocol
implementation and the lack of previous
experiences with TGC markedly inﬂu-
enced the outcomes of both studies
(7,9,20,21).
To our knowledge, our study is the
ﬁrst to compare head-to-head three well-
Table 2—Study blood glucose control data
Matias Bath eMPC
Baseline blood glucose 7.9  0.4 8.0  0.2 8.1  0.6
Entire study blood glucose control data (or 48 h)
Average blood glucose (mmol/l) 6.7  0.1 6.5  0.2 5.9  0.2*†
Sampling interval (h) 2.0  0.1 1.7  0.1 2.1  0.1
Time to target range (h) 10.9  1.0 12.3  1.9* 8.8  2.2†
Time in target range (%) 38.2  2.9 39.7  3.1 46.0  3.0*†
Blood glucose control data after reaching the
target range (4.4–6.1 mmol/l)
Average blood glucose (mmol/l) 6.2  0.1 5.8  0.1* 5.2  0.1*†
Sampling interval (h) 2.1  0.1 1.8  0.1* 2.3  0.1†
Time to target range (h) 48.4  3.2 55.5  3.2 62.8  4.4*†
Time in risk of hypoglycemia (2.9–4.3
mmol/l) (%) 10.9  1.5 13.1  1.6 22.2  1.9*†
Time in hypoglycemia (2.9 mmol/l) (%) 0.4  0.2 0.4  0.3 0.0  0.0
Severe hypoglycemia episodes (2.3 mmol/l) 1 2 0
Time in risk of hyperglycemia (6.2–8.3
mmol/l) (%) 27.5  2.2 24.5  2.4 13.7  2.6*†
Time in hyperglycemia (8.3 mmol/l) (%) 12.8  2.2 6.5  2.0* 1.3  1.2*†
Data are expressed as means  SEM. Arterial blood glucose was measured as prescribed by each protocol in
1- to 4-h intervals. The patients were followed for up to 48 h (mean follow-up time 46.7  0.5 h for the
Matias, 45.7  0.7 h for the Bath, and 47.2  0.3 h for the eMPC protocols). The percentages of time in the
target range were calculated as number of in-range values of each patient/number of measurements  100.
*StatisticallysigniﬁcantdifferencefromtheMatiasprotocol.†StatisticallysigniﬁcantdifferencefromtheBath
protocol (P  0.05).
Figure 1— Blood glucose concentrations and time to target range, expressed as means  SEM, in patients after cardiac surgery controlled by the
Matias, Bath, and eMPC protocols.
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cols. We used the simplest and possibly
the most straightforward way to analyze
the data and calculated the average blood
glucose and the percentage of time within
the target range. For the sake of clarity
andtransparency,wedidnotuseanydata
interpolation and/or other more sophisti-
cated data analysis tools.
Eachprotocoltestedinourstudyrep-
resented a principally different approach
to glucose control. The Matias algorithm
differs from the other two protocols by
combining continuous intravenous insu-
lin infusion with intravenous insulin bo-
luses. This approach might have a
possible advantage in the ability to
quickly achieve the target range. Interest-
ingly, although the Matias protocol
achieved the target range 1.5 h earlier
than the Bath protocol, it was still signif-
icantly worse than the computer-based
eMPC algorithm that achieved the target
range 2 h earlier than the Matias protocol
without using intravenous insulin bo-
luses. The superior performance of the
eMPCalgorithmwasnotaccompaniedby
a higher risk of hypoglycemia. In fact, the
opposite was true because no severe hy-
poglycemia was detected in the eMPC al-
gorithm group (Table 2).
The principal difference between the
Bath protocol and the Matias protocol is
that the insulin dose is based on the rela-
tive change of the blood glucose between
the two measurements rather than on the
absolute glucose concentration itself. A
majoradvantageoftheBathprotocolmay
be that relative blood glucose change may
give a better indication of the high vari-
ability of patients’ insulin resistance and
the nature and severity of their illness es-
pecially in comparison with the Matias
protocol. A direct comparison of the Bath
algorithm with absolute glucose value–
based Matias protocol showed slightly
betterperformanceoftheformerwithsig-
niﬁcantly lower mean blood glucose and
time in hyperglycemia after reaching the
targetrange.Conversely,thetimetoreach
the target range was longer and the sam-
pling interval was shorter with the Bath
protocol than with the Matias protocol.
The eMPC protocol also uses the rate
of change in blood glucose, although this
is not carried out in an explicit manner as
withtheBathprotocol.Instead,theeMPC
algorithm derives insulin sensitivity and
other physiologically relevant parameters
from up to a 10-h blood glucose proﬁle.
The eMPC algorithm achieved signiﬁ-
cantly better results compared with the
other two protocols in the majority of the
most important parameters (Table 2): in
effectiveness (time to target range), in ef-
ﬁciency of glycemia management after
reachingthetargetrange(meanglycemia,
time in target range, time in risk of hyper-
glycemia, and time in hyperglycemia),
and in sampling interval. Improved glu-
cose control with the use of the eMPC
algorithm was accompanied by a longer
time within the range at higher risk of
hypoglycemia, but the occurrence of
moderate or severe hypoglycemia was
zero in the eMPC group, suggesting the
high level of safety of this protocol.
Overall, compared with some of the
previously published studies, all three pro-
tocols were able to achieve reasonably tight
glucose control without an excessive risk of
hypoglycemia and/or other complications
(21). The low rate of hypoglycemic events
and the overall results in our study could
have been partially due to a relatively high
constant rate of glucose infusion adminis-
tered throughout the study. A constant
high-rateglucoseinfusionisexpectedtoac-
celerate glucose turnover and the overall
system response. In consequence, this fea-
tureoftheprotocolshouldimprovethesta-
bility of glucose control, especially under
the routine protocol, whereas the eMPC
protocol should be less affected. It is thus
possible that the overall outcome of the
three protocols tested would differ under
theconditionsofalowerparenteralglucose
administration, and the results thus cannot
be directly applicable to other patient
populations.
From the user point of view, the ma-
jor difference between the eMPC and
other protocols is the nonﬁxed sampling
interval of the eMPC algorithm. In typical
ICU settings, there is usually a time win-
dow within which any therapeutic and/or
other procedure including TGC should
occur. In reality, such a standard “ﬁxed”
interval then may vary considerably. The
eMPC algorithm, with its bedside screen
interface continuously showing time to
Figure 2— Blood glucose concentrations, expressed as means  SEM, in patients after cardiac surgery, controlled by the Matias, Bath, and eMPC
protocols during the entire 48-h postoperative period. Average time within the target range was 38.2  2.9% for the Matias protocol, 39.7  3.1%
for the Bath protocol, and 45.98  3.0% for the eMPC protocol.
Comparison of protocols for glycemic control
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portanceofon-timesampling.Thenurses
then tend to adapt their activities so that
they can fulﬁll eMPC instructions within
therequiredtimeframe.Forthesakeofour
comparative study, we asked our nurses to
be as accurate as possible in fulﬁlling all re-
quirements of the algorithms, especially
with respect to timing of blood glucose
measurements. Thus, the study conditions
for both the Matias and Bath algorithms
couldhavebeensomehowbettercompared
with a “real-life” situation.
Because two of the three protocols
tested were partially implemented in our
ICU previously, our study does not an-
swer the question of how difﬁcult it is to
implement the protocols from the very
beginning. The 3-month implementation
period was long enough to safely use the
BathprotocolunderourICUsettings.We
suggest that an appropriate implementa-
tion period and previous experience of
our ICU staff with TGC may be the rea-
sons that the quality and safety of glucose
control in our study were signiﬁcantly
better than the results of most of the pre-
viously published studies (22–25).
In summary, we demonstrate that the
computer-based eMPC algorithm with a
variable sampling interval is more effec-
tive in achieving and maintaining TGC in
patients after cardiac surgery than both
the relative glucose levels change–based
Bath protocol and the absolute glucose
value–based Matias protocol. Overall, all
three protocols were able to achieve rea-
sonable blood glucose control without
any major side effects.
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